← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
BROADWOOD CAPITAL INC
10% Owner
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001278387
Purchase history
- Companies traded
- 3
- Purchases · 12M
- 7
- Purchases · 24M
- 20
- Average purchase
- $6.6M
- Median purchase
- $2.9M
- Gross purchase value
- $131.1M
Companies: Insight Molecular Diagnostics Inc. | Lineage Cell Therapeutics, Inc. | Oncocyte Corp | STAAR SURGICAL CO
20 SEC accession(s) · 20 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-04-27 | Insight Molecular Diagnostics Inc. | IMDX | 10% Owner | $2.0M | Open filing |
| 2026-04-20 | Insight Molecular Diagnostics Inc. | IMDX | 10% Owner | $653.2K | Open filing |
| 2026-03-13 | STAAR SURGICAL CO | STAA | 10% Owner | $12.3M | Open filing |
| 2026-02-12 | Insight Molecular Diagnostics Inc. | IMDX | 10% Owner | $3.0M | Open filing |
| 2026-01-13 | STAAR SURGICAL CO | STAA | 10% Owner | $606.0K | Open filing |
| 2026-01-08 | STAAR SURGICAL CO | STAA | 10% Owner | $8.8M | Open filing |
| 2025-11-21 | STAAR SURGICAL CO | STAA | 10% Owner | $41.1M | Open filing |
| 2025-04-10 | STAAR SURGICAL CO | STAA | 10% Owner | $2.9M | Open filing |
| 2025-04-07 | STAAR SURGICAL CO | STAA | 10% Owner | $13.6M | Open filing |
| 2025-04-02 | STAAR SURGICAL CO | STAA | 10% Owner | $941.3K | Open filing |
| 2025-03-28 | STAAR SURGICAL CO | STAA | 10% Owner | $2.0M | Open filing |
| 2025-03-25 | STAAR SURGICAL CO | STAA | 10% Owner | $2.4M | Open filing |
| 2025-03-20 | STAAR SURGICAL CO | STAA | 10% Owner | $3.6M | Open filing |
| 2025-03-06 | STAAR SURGICAL CO | STAA | 10% Owner | $481.9K | Open filing |
| 2025-03-03 | STAAR SURGICAL CO | STAA | 10% Owner | $11.3M | Open filing |
| 2025-02-14 | STAAR SURGICAL CO | STAA | 10% Owner | $6.3M | Open filing |
| 2025-02-10 | Oncocyte Corp | OCX | 10% Owner | $10.6M | Open filing |
| 2025-01-28 | Lineage Cell Therapeutics, Inc. | LCTX | 10% Owner | $6.0M | Open filing |
| 2025-01-16 | STAAR SURGICAL CO | STAA | 10% Owner | $630.7K | Open filing |
| 2024-12-18 | STAAR SURGICAL CO | STAA | 10% Owner | $1.9M | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
No completed point-in-time price outcome is available yet.
Research patterns
- First purchase in 12M
- 1/17
- Large purchase ≥ $100k
- 20/20
- Cluster buying · 15D
- 20/20
- Buying the dip
- 0/—
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.